- |||||||||| carotuximab IV (ENV-105) / Kairos Pharma
Trial completion, Combination therapy, IO biomarker: Sorafenib and TRC105 in Hepatocellular Cancer (clinicaltrials.gov) - Jan 23, 2018 P1/2, N=27, Completed, Active, not recruiting --> Terminated Active, not recruiting --> Completed
- |||||||||| TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion, Trial primary completion date: MispheC: Efficacy Study of Intra-hepatic Administration of Therasphere (clinicaltrials.gov) - Jan 19, 2018 P2, N=41, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Dec 2016
- |||||||||| ribavirin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Ribados: Ribavirin, Its Dosing Regime (clinicaltrials.gov) - Jan 9, 2018 P4, N=15, Completed, Recruiting --> Completed | Phase classification: P2 --> P2a | N=36 --> 47 | Trial primary completion date: Sep 2017 --> Feb 2017 Recruiting --> Completed | N=20 --> 15 | Trial primary completion date: Dec 2011 --> Dec 2012
- |||||||||| Aphthasol (amlexanox) / Abeona Therap, Esteve
Clinical protocol, Enrollment closed: Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients (clinicaltrials.gov) - Dec 19, 2017 P2, N=42, Active, not recruiting, Trial primary completion date: Jul 2011 --> Sep 2010 Completed --> Active, not recruiting
- |||||||||| Trial completion, Trial primary completion date: Gilead Sustained Virologic Response (SVR) Registry (clinicaltrials.gov) - Dec 12, 2017
P=N/A, N=6625, Completed, Completed --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2020 --> Nov 2017
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Genetics of Fatty Liver Disease in Children (clinicaltrials.gov) - Dec 8, 2017
P=N/A, N=381, Completed, Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Completed | N=1000 --> 381 | Trial primary completion date: Dec 2020 --> Jul 2017
- |||||||||| Enrollment change, Trial initiation date, Trial termination: Antineoplaston Therapy in Treating Patients With Primary Liver Cancer (clinicaltrials.gov) - Nov 21, 2017
P2, N=3, Terminated, Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Nov 2017 N=40 --> 3 | Initiation date: Aug 1998 --> Mar 1977 | Active, not recruiting --> Terminated; Slow accrual
- |||||||||| pentoxifylline / Generic mfg., enoxaparin sodium / Generic mfg., ursodeoxycholic acid / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: ELDORADO: Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity (clinicaltrials.gov) - Nov 20, 2017 P2, N=22, Completed, N=40 --> 3 | Initiation date: Aug 1998 --> Mar 1977 | Active, not recruiting --> Terminated; Slow accrual Recruiting --> Completed | N=44 --> 22 | Trial primary completion date: Jun 2012 --> Nov 2017
- |||||||||| Trial completion, Trial primary completion date: Pediatric Liver Database (clinicaltrials.gov) - Nov 18, 2017
P=N/A, N=401, Completed, Recruiting --> Completed | N=44 --> 22 | Trial primary completion date: Jun 2012 --> Nov 2017 Recruiting --> Completed | Trial primary completion date: Jun 2018 --> Sep 2016
- |||||||||| Enrollment closed, Enrollment change, Trial primary completion date: HepART-RCT: Hepatitis C Alcohol Reduction Treatment (clinicaltrials.gov) - Nov 8, 2017
P=N/A, N=182, Active, not recruiting, Recruiting --> Completed | N=56 --> 28 Recruiting --> Active, not recruiting | N=279 --> 182 | Trial primary completion date: Mar 2019 --> Aug 2018
- |||||||||| floxuridine / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Surgery, Metastases: Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery (clinicaltrials.gov) - Nov 7, 2017 P1/2, N=28, Active, not recruiting, N=60 --> 0 | Active, not recruiting --> Withdrawn Trial primary completion date: Nov 2017 --> Jul 2018
- |||||||||| rifampicin / Generic mfg.
Trial completion, Trial primary completion date: The Effects of PXR Activation on Hepatic Fat Content (clinicaltrials.gov) - Nov 1, 2017 P4, N=16, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Jan 2017
- |||||||||| Phase classification, Trial initiation date, Trial primary completion date: Dietary Intervention and Intestinal Microbiota in Non-alcoholic Fatty Liver (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=20, Completed, Recruiting --> Completed Phase classification: P2 --> P=N/A | Initiation date: Jul 2011 --> Jul 2013 | Trial primary completion date: Dec 2014 --> Aug 2016
- |||||||||| Tyzeka (telbivudine) / Novartis
Trial initiation date, Trial primary completion date: STEN: A Two-year Study of Telbivudine in HBeAg Negative Hepatitis (clinicaltrials.gov) - Oct 24, 2017 P4, N=360, Completed, No longer recruiting --> Completed Initiation date: Sep 2011 --> Jan 2011 | Trial primary completion date: Feb 2013 --> Feb 2014
- |||||||||| lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment change, Trial initiation date: Prevention of Recurrent Hepatitis B After Liver Transplantation (clinicaltrials.gov) - Oct 18, 2017 P=N/A, N=317, Completed, Recruiting --> Completed | N=150 --> 75 N=500 --> 317 | Initiation date: Jun 2001 --> Mar 2001
|